Patil Mallikarjun, Sheth Keyur A, Krishnamurthy Adarsh C, Devarbhavi Harshad
Department of Gastroenterology, St. John's Medical College Hospital, Bangalore 560034, India.
J Clin Exp Hepatol. 2013 Dec;3(4):321-36. doi: 10.1016/j.jceh.2013.06.002. Epub 2013 Jul 6.
Wilson disease is a rare, inherited autosomal recessive disease of copper metabolism and may be more common where consanguinity is prevalent. Much has been known about the disease after it was first described by Kinnier Wilson as 'progressive lenticular degeneration in 1912. Over 500 mutations of the ATP7B gene has been identified with no clear genotype to phenotype correlation. Loss of ATP7B function leads various grades of reduced biliary excretion of copper and reduced incorporation of copper into ceruloplasmin; accumulation and toxicity of copper in the liver, brain and other tissues results in liver toxicity and other myriad manifestations of the disease. The clinical features may vary from asymptomatic state to chronic liver disease, acute liver failure, neuropsychiatric manifestations and hemolytic anemia. Diagnosis is based on the combination of clinical sign's, biochemical features, histologic findings and mutation analysis of ATP7B gene. Subtle geographical differences exist with a disproportionate proportion of children presenting with acute liver failure. A high index of suspicion is needed for an early diagnosis. Ratios of biochemical indices for early diagnosis need validation across geographical regions and may not be particularly applicable in children. Better biomarkers or the need for tests for early detection of ALF persists. Drugs used in the treatment of Wilson disease include copper chelating agents such as d-Penicillamine, trientine and zinc salt. Untreated Wilson disease uniformly leads to death from liver disease or severe neurological disability. Early recognition and treatment has excellent prognosis. Liver transplantation is indicated in acute liver failure and end stage liver disease. Family screening in order to detect the disorder in the first-degree relatives is warranted. This review provides an overview of different aspects of Wilson disease including geographical differences in presentations and clinical management and the limitations of currently available tests.
威尔逊病是一种罕见的、遗传性常染色体隐性铜代谢疾病,在近亲结婚普遍的地区可能更为常见。自1912年金尼尔·威尔逊首次将其描述为“进行性豆状核变性”以来,人们对这种疾病已经有了很多了解。现已鉴定出ATP7B基因的500多种突变,但基因型与表型之间没有明确的相关性。ATP7B功能丧失导致不同程度的胆汁铜排泄减少以及铜掺入铜蓝蛋白减少;铜在肝脏、大脑和其他组织中的蓄积和毒性导致肝毒性及该疾病的其他多种表现。临床特征可能从无症状状态到慢性肝病、急性肝衰竭、神经精神表现和溶血性贫血不等。诊断基于临床体征、生化特征、组织学发现以及ATP7B基因突变分析的综合判断。存在细微的地域差异,表现为出现急性肝衰竭的儿童比例过高。早期诊断需要高度的怀疑指数。用于早期诊断的生化指标比值需要在不同地理区域进行验证,可能并不特别适用于儿童。仍然需要更好的生物标志物或早期检测急性肝衰竭的检测方法。用于治疗威尔逊病的药物包括铜螯合剂,如d-青霉胺、曲恩汀和锌盐。未经治疗的威尔逊病最终会导致死于肝病或严重的神经功能残疾。早期识别和治疗预后良好。急性肝衰竭和终末期肝病患者需要进行肝移植。有必要对家族成员进行筛查,以便在一级亲属中检测出该疾病。本综述概述了威尔逊病的不同方面,包括临床表现的地域差异、临床管理以及现有检测方法的局限性。